Sihuan Pharmaceutical and NeuroVive to develop cardio-cerebral vascular drugs

Sihuan Pharmaceutical and NeuroVive have announced a collaborative agreement that should help to bring two new cardio-cerebral vascular drugs to market.

Sihuan Pharmaceutical Holdings Group has announced a collaboration agreement with NeuroVive Pharmaceutical to develop two new cardio-cerebral vascular products.

Sihuan Pharmaceutical currently holds the largest cardio-cerebral vascular drug franchise in China's prescription market, while NeuroVive is an international mitochondrial pharmaceutical development company.

Under the terms of the agreement, Sihuan Pharmaceutical will gain an exclusive licence to develop, market and sell CicloMulsion - for the treatment of heart reperfusion injuries - and NeuroSTAT - for traumatic brain injuries - in China.

CicloMulsion is currently undergoing phase-III clinical testing, while NeuroSTAT is the subject of phase-II trials.
Both products contain cyclosporine A and work by protecting the mitochondria of cells, thereby preserving the production of energy and enabling damaged cells in the heart and brain to repair themselves.

Dr Che Fengsheng, chairman and chief executive officer of Sihuan Pharmaceutical, said: "The important collaborative agreement with a renowned international pharmaceutical development company marks a breakthrough for our business development.

"The collaboration will bring together Sihuan Pharmaceutical's competitive advantages in product development, marketing promotion and distribution network and NeuroVive's advanced drug development technology."

Mikael Bronnegard, chief executive officer of NeuroVive, also welcomed the agreement, describing it as "strong validation of the huge potential of mitochondrial medicine".